This article is more than 5 years old. Information may no longer be current.
ASH chooses minority resident hematology award program participants
Click Here to Manage Email Alerts
ASH selected three resident physicians to participate in the 2017 ASH Minority Resident Hematology Award Program.
The program offers support to underrepresented minority residents to conduct hematology research.
Participants will receive $7,000 to help cover the costs of research and travel expenses to the ASH Annual Meeting and Exposition in December, at which they will present results of their projects.
Each resident will be paired with a research mentor who will oversee their project, as well as a career development mentor who will guide them through their program experience.
“The ASH Minority Resident Hematology Award Program establishes a new opportunity for outstanding resident physicians to further develop their passion for hematology,” ASH President Kenneth C. Anderson, MD, director of Lebow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center at Dana-Farber Cancer Institute, said in a society-issued press release. “Providing them sustained support through training will encourage these talented hematologists to continue to pursue hematology, and it will give them the extra support they need to excel in their careers.”
This year’s program participants are:
- Owhofasa Agbedia, MD, MPH, of Howard University. Agbedia will study the incidence, survival and prevalence of hematologic malignancies among minority populations. Agbedia’s research mentor will be Patricia Oneal, MD, of the FDA’s Center for Drug Evaluation and Research. His career development mentor will be Deepika S. Darbari, MD, of Children’s National Medical Center/George Washington University School of Medicine.
- Elisa Quiroz of Beaumont Health in Dearborn, Michigan. Quiroz will study variations in microRNA expression in Latin American individuals with acute lymphoblastic leukemia. Quiroz’s research mentor will be Dan Douer, MD, of University of Southern California Keck School of Medicine/Norris Comprehensive Cancer Center. Her career development mentor will be Ivan Maillard, MD, PhD, of University of Michigan.
- Samuel Wilson, MD, of University of Michigan health System. Wilson will study the role of Duffy antigen phenotype in clinical outcomes of individuals with sickle cell disease on hydroxyurea therapy. Wilson’s research mentor will be Andrew Campbell, MD, of University of Michigan Health System/C.S. Mott Children’s Hospital, and his career development mentor will be Scott D. Gitlin, MD, of University of Michigan Medical School.